504 related articles for article (PubMed ID: 25010260)
1. YAP activation is an early event and a potential therapeutic target in liver cancer development.
Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
[TBL] [Abstract][Full Text] [Related]
2. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
[TBL] [Abstract][Full Text] [Related]
3. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
[TBL] [Abstract][Full Text] [Related]
4. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
Ahn EY; Kim JS; Kim GJ; Park YN
Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
[TBL] [Abstract][Full Text] [Related]
5. High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis.
Chen R; Zhu S; Fan XG; Wang H; Lotze MT; Zeh HJ; Billiar TR; Kang R; Tang D
Hepatology; 2018 May; 67(5):1823-1841. PubMed ID: 29149457
[TBL] [Abstract][Full Text] [Related]
6. Role of YAP Activation in Nuclear Receptor CAR-Mediated Proliferation of Mouse Hepatocytes.
Abe T; Amaike Y; Shizu R; Takahashi M; Kano M; Hosaka T; Sasaki T; Kodama S; Matsuzawa A; Yoshinari K
Toxicol Sci; 2018 Oct; 165(2):408-419. PubMed ID: 29893953
[TBL] [Abstract][Full Text] [Related]
7. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
8. Yes-associated protein/TEA domain family member and hepatocyte nuclear factor 4-alpha (HNF4α) repress reciprocally to regulate hepatocarcinogenesis in rats and mice.
Cai WY; Lin LY; Hao H; Zhang SM; Ma F; Hong XX; Zhang H; Liu QF; Ye GD; Sun GB; Liu YJ; Li SN; Xie YY; Cai JC; Li BA
Hepatology; 2017 Apr; 65(4):1206-1221. PubMed ID: 27809333
[TBL] [Abstract][Full Text] [Related]
9. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
[TBL] [Abstract][Full Text] [Related]
10. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
Wong KF; Liu AM; Hong W; Xu Z; Luk JM
Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
[TBL] [Abstract][Full Text] [Related]
11. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.
Marquard S; Thomann S; Weiler SME; Bissinger M; Lutz T; Sticht C; Tóth M; de la Torre C; Gretz N; Straub BK; Marquardt J; Schirmacher P; Breuhahn K
Cell Commun Signal; 2020 Oct; 18(1):166. PubMed ID: 33097058
[TBL] [Abstract][Full Text] [Related]
12. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
[TBL] [Abstract][Full Text] [Related]
13. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL
Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells.
Zhang T; Zhang J; You X; Liu Q; Du Y; Gao Y; Shan C; Kong G; Wang Y; Yang X; Ye L; Zhang X
Hepatology; 2012 Dec; 56(6):2051-9. PubMed ID: 22707013
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
[TBL] [Abstract][Full Text] [Related]
16. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice.
Kowalik MA; Saliba C; Pibiri M; Perra A; Ledda-Columbano GM; Sarotto I; Ghiso E; Giordano S; Columbano A
Hepatology; 2011 Jun; 53(6):2086-96. PubMed ID: 21391223
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma.
Zhao F; Yang Z; Chen Y; Zhou Q; Zhang J; Liu J; Wang B; He Q; Zhang L; Yu Y; Liu P
World Neurosurg; 2018 Sep; 117():e269-e279. PubMed ID: 29902598
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma.
Huo X; Zhang Q; Liu AM; Tang C; Gong Y; Bian J; Luk JM; Xu Z; Chen J
Oncol Rep; 2013 Feb; 29(2):840-6. PubMed ID: 23232767
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC).
Petrelli A; Perra A; Cora D; Sulas P; Menegon S; Manca C; Migliore C; Kowalik MA; Ledda-Columbano GM; Giordano S; Columbano A
Hepatology; 2014 Jan; 59(1):228-41. PubMed ID: 23857252
[TBL] [Abstract][Full Text] [Related]
20. TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma.
Dong Q; Fu L; Zhao Y; Xie C; Li Q; Wang E
Oncotarget; 2017 Feb; 8(9):15689-15703. PubMed ID: 28152516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
